Special Issue "Cancer Vaccine and Immunotherapy: From NK Cells to CAR T Cells"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 31 January 2023 | Viewed by 40

Special Issue Editor

Dr. Siva Karthik Varanasi
E-Mail Website
Guest Editor
Salk Institute for Biological Studies, San Diego, CA 92037, USA
Interests: liver cancer; T cells; metabolism

Special Issue Information

Dear Colleagues,

Our immune system constantly defends our body from threats, including cancer. Under circumstances that are not entirely known, cancer cells can develop ways to evade immune responses, which can result in their uncontrolled and malignant growth. A better understanding of how tumor cells suppress the function of immune cells, especially killer T cells, could lead to strategies with immense therapeutic potential.

Immunotherapeutic strategies, including immune checkpoint inhibitors (ICI), adoptive cell therapy (ACT), and monoclonal antibodies, have dramatically revolutionized cancer treatments. In particular, immunotherapy with ICI has strongly changed the treatment of some solid tumors, while ACT with CAR or engineered T cells has shown great potential in the treatment of patients with hematologic malignancies.

Natural killer (NK) cells are critical effector cells that mediate anti-tumour immunity via direct cytotoxicity, antibody-dependent cellular cytotoxicity, and the promotion of adaptive immune responses. Strategies to enhance NK cell function are at the cutting edge of translational cancer research, and the current approaches include natural killer cell engagers, CAR-NK cells, cytokine-mediated NK cell stimulation, and checkpoint blockades.

This Special Issue will cover all aspects relevant to NK cells, CAR T cells, and cancer immunotherapy. We encourage submissions related to the progress in and development of cancer vaccine research in order to explore the obstacles in cancer vaccine research and promote the efficacy of cancer vaccines. At the same time, it also aims to provide a global vision on the therapeutic potential of cancer vaccination.

All scientists working in these fields are warmly welcomed to submit their manuscripts to our Special Issue.

Dr. Siva Karthik Varanasi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Back to TopTop